๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Adjuvant chemotherapy for uroepithelial transitional cell carcinoma

โœ Scribed by Manabu Kuriyama; Toshimi Takeuchi; Shigeru Fujihiro; Yoshinori Fujimoto; Ikuo Shinoda; Yoshito Takahashi; Shin-ichiro Yamada; Tsuneo Nishiura

Publisher
Springer
Year
1987
Tongue
English
Weight
382 KB
Volume
20
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Chemotherapy resistant transitional cell
Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention
โœ Christopher J. Logothetis ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 292 KB

alpha-Interferon combined with 5-fluorouracil results in significant antitumoral activity in metastatic bladder carcinoma refractory to standard MVAC chemotherapy. As a single agent, alpha-interferon is ineffective for invasive or metastatic disease, but appears to contribute to the increased respon

Systemic chemotherapy of transitional ce
Systemic chemotherapy of transitional cell carcinoma of the urothelium
โœ William M. Brinkley; Frank M. Torti ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 3 views

Although the incidence of bladder cancer has increased in recent years, survival has also improved. Chemotherapy has made a substantial impact on this disease and now is used in patients with advanced or metastatic disease as well as in select patients with high-risk muscle invasive disease. While c

Chemotherapy of advanced transitional ce
Chemotherapy of advanced transitional cell carcinoma of the uroepithelium
โœ Frank M. Torti; W. Graydon Harker ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› Springer ๐ŸŒ English โš– 390 KB

Activity has been demonstrated for both single agents and combination chemotherapy in advanced transitional cell carcinoma of the uroepithelium. Regimens are palliative; duration of response has been modest, usually ranging from 3 to 8 months. There are few complete responders; occasional patients r